Additional file 3 of Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
收藏数据链接：
官方服务：
资源简介：
Additional file 3. Clinical Response.
创建时间：
2023-04-10
